Promising combo therapy for multiple myeloma shows potential in early trial

NCT ID NCT02405364

First seen Apr 16, 2026 · Last updated Apr 25, 2026 · Updated 2 times

Summary

This study tested a three-drug combination (carfilzomib, lenalidomide, and dexamethasone) given before and after a stem cell transplant in 46 newly diagnosed multiple myeloma patients aged 65 or younger. The goal was to see how many patients achieved a very deep remission after the full treatment plan. Results will help decide if this approach should be tested in larger trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHRU Dijon

    Dijon, France

  • CHRU Hôtel Dieu

    Nantes, France

  • CHU Grenoble

    Grenoble, France

  • CHU Henri Mondor

    Créteil, France

  • CHU de Toulouse

    Toulouse, 31000, France

  • Hôpital Bretonneau

    Tours, France

  • Hôpital Claude Huriez

    Lille, France

  • Hôpital Saint-Antoine

    Paris, France

  • Hôpital de Hautepierre

    Strasbourg, France

  • Hôpital de Pontchaillou

    Rennes, France

  • University hospital of Toulouse

    Toulouse, 31000, France

Conditions

Explore the condition pages connected to this study.